Le Tourneau, C
Dreno, B
Kirova, Y
Grob, J J
Jouary, T
Dutriaux, C
Thomas, L
Lebbé, C
Mortier, L
Saiag, P
Avril, M F
Maubec, E
Joly, P
Bey, P
Cosset, J M
Sun, J S
Asselain, B
Devun, F
Marty, M E
Dutreix, M
Article History
Received: 4 February 2016
Revised: 11 March 2016
Accepted: 8 April 2016
First Online: 3 May 2016
Competing interests
: BD reports grants and personal fees from Roche, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from GlaxoSmithKline, outside the submitted work. CL reports personal fees from Roche, GlaxoSmithKline, Merck Sharp and Dhome, Bristol-Myers Squibb outside the submitted work. FD is employee of DNA Therapeutics; JMC, JSS and MD are cofounders of DNA Therapeutics, the company which holds the patent for DT01. MEM served as a consultant for DNA Therapeutics, Oncoethics, Merck Sharp and Dhome, Pfizer and Roche laboratories. The other authors declare no conflict of interest.